Results 51 to 60 of about 130,065,242 (295)

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Gene transfer vectors targeted to human prostate cancer : do we need better preclinical testing systems? [PDF]

, 2010
Destruction of cancer cells by genetically modified viral and nonviral vectors has been the aim of many research programs. The ability to target cytotoxic gene therapies to the cells of interest is an essential prerequisite, and the treatment has always ...
Essand, M, Maitland, N, van Weerden, Wytske, Evans, Helen, Chambers, Karen F., Leadley, R, van Weerden, Wytske; id_orcid, Danielsson, Angelika,, Leadley, Regina, Maitland, Norman, Simpson-Holley, Martha, Georgopoulos, Lindsay, Evans, H, Danielsson, Angelika, Simpson-Holley, M, Kraaij, Robert, Chambers, Karen, Chambers, K, Essand, Magnus, Danielsson, A, Kraaij, Robert; id_orcid, de Ridder, Corrina, Bangma VERVALLEN, CH, Bangma, Chris H., Bangma, Chris, Georgopoulos, L, Essand, Magnus,, Martha Simpson-Holley, Angelika Danielsson, Magnus Essand, Wytske van Weerden, Helen Evans, Corrina de Ridder, Karen Chambers, Lindsay Georgopoulos, Chris H. Bangma, Regina Leadley, Robert Kraaij, Norman Maitland   +38 more
core   +1 more source

Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation

Pharmaceutics, 2023
Contemporary trends in combinatorial chemistry and the design of pharmaceuticals targeting brain disorders have favored the development of drug candidates with increased lipophilicity and poorer water solubility, with the expected improvement in delivery
Tanja Ilić, Jelena B. Đoković, Ines Nikolić, Jelena R. Mitrović, Ivana Pantelić, Snežana D. Savić, Miroslav M. Savić   +6 more
doaj   +1 more source

A novel in vitro model for preclinical testing of the hemocompatibility of intravascular stents according to ISO 10993-4

Journal of Materials Science: Materials in Medicine, 2011
Subacute stent thrombosis, caused by undesired interactions between blood and the stent surface, is a major concern in the first few weeks following coronary artery stent implantation. The aim of this study was to establish a novel in vitro model for hemocompatibility testing of coronary artery stents according to ISO 10993-4.
Stefan, Sinn, Torsten, Scheuermann, Stephan, Deichelbohrer, Gerhard, Ziemer, Hans P, Wendel   +4 more
openaire   +2 more sources

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Preclinical Testing of Novel Radiotracers for Positron Emission Tomography (PET)

, 2017
Preclinical tests of novel radiotracers in experimental animals are required tomove tracer candidates from the stage of in vitro testing to the stage of toxicitytesting and finally studies in human volunteers.
de Vries, Erik, Doorduin, Janine, van Waarde, Aren, de Vries, Erik; id_orcid, Sijbesma, Jurgen, Sijbesma, Jurgen; id_orcid, Elsinga, Philippus, van Waarde, Aren; id_orcid, Doorduin, Janine; id_orcid   +8 more
core   +1 more source

Progress of 3D Organoid Technology for Preclinical Investigations: Towards Human In Vitro Models

, 2022
Currently, with an increased requirement for new therapeutic strategies, preclinical drug testing or screening platforms have rapidly evolved in recent years.
Wang, Xin, Abraham, Sabu; id_orcid, Liu, Yingjuan; id_orcid, Keavney, Bernard D., Xu, Honglin, Honglin Xu, Xin Wang, Bernard D. Keavney, Yingjuan Liu, Sabu Abraham   +9 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Development of a Physiologic In-Vitro Testing Methodology for Assessment of Cervical Spine Kinematics [PDF]

, 2013
In-vitro biomechanical testing has been critical in the design and evaluation of spinal surgical instrumentation, however determination of realistic physiologic loading levels has proven difficult outside of the in-vivo setting.
Bell, Kevin
core